Invited Speakers

	Stephen D. Nimer (Sylvester Comprehensive Cancer Center, Oscar de la Renta Endowed Chair in Cancer Research/Biochemistry & Molecular Biology, University of Miami Miller School of Medicine, USA) Special Lecture "Epigenetic targets in AML/MDS"
	Martin S. Tallman (Memorial Sloan Kettering Cancer Center, USA) ASH Special Lecture "Novel therapeutic strategies in acute myeloid leukemia"
	John Gribben (Barts Cancer Institute, UK) EHA Special Lecture "The Unique Tumor Microenvironment in B Cell Malignancies"
	Elli Papaemmanuil (Memorial Sloan Kettering Cancer Center, USA) Presidential Symposium 1:Etiological Aspects of Leukemia and Myeloid Neoplasms "Biological and clinical implications of clonal hematopoiesis in cancer patients"
	Marc H.G.P. Raaijmakers (Dept. of Hematology, Erasmus MC Cancer Institute, the Netherlands) Presidential Symposium 1:Etiological Aspects of Leukemia and Myeloid Neoplasms "Niche contributions to clonal evolution in MDS"
	Michel Sadelain (Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, USA) Symposium 1:Recent Development of Cell and Gene Therapy for Hematological Disorders "CAR T cells: the emergence of synthetic immunity"
	Luigi Naldini (San Raffaele Telethon Institute for Gene Therapy, Italy) Symposium 1:Recent Development of Cell and Gene Therapy for Hematological Disorders "Targeted Gene Editing of Hematopoietic Stem Cells for the Treatment of Inherited Disease"
	Sigbjørn Berentsen (Department of Research and Innovation, Haugesund Hospital, Haugesund, Norway) Symposium 2:Hemolytic Anemia: Molecular Pathogenesis and New Treatment "Cold agglutinin disease: An update on pathogenesis and future prospects on therapy"
	Michael Heuser (Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation / Hannover Medical School, Hannover, Germany) Symposium 3:Relapse After Allogeneic HSCT: Challenges and New Directions "Measurable residual disease monitoring by NGS"
	Luca Vago (Unit of Immunogenetics, Leukemia Genomics and Immunobiology, IRCCS San Raffaele Scientific Institute, Italy / Hematology and Bone Marrow Transplantation Unit, IRCCS San Raffaele Scientific Institute) Symposium 3:Relapse After Allogeneic HSCT: Challenges and New Directions "Mechanisms of immune evasion and relapse after allogeneic HCT"
	Sattva S Neelapu (Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, USA) Symposium 4:Current Achievements and Future Prospects of DLBCL Research "Optimization of CAR-T therapy for relapsed/refractory DLBCL"
	Peter Johnson (Cancer Research UK Centre, Southampton General Hospital, UK) Symposium 4:Current Achievements and Future Prospects of DLBCL Research "Will molecular typing be useful for optimising first line therapy of diffuse large B-cell lymphoma?"
	Andrew Wei (The Alfred Hospital and Monash University, Melbourne, Australia) Symposium 5:Novel Molecular-Targeted Therapy for AML "BH3-mimetics herald a new therapeutic era in acute myeloid leukemia"
	Naval Daver (Leukemia, The University of Texas MD Anderson Cencer Center, USA) Symposium 5:Novel Molecular-Targeted Therapy for AML "Molecular targeted therapies in AML: combination approaches may hold the key"
	Bertie Göttgens (Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, UK) JSH-EHA Joint Symposium (Symposium 6):Evolving Paradigm for Blood Cell Differentiation "Network control of normal and leukaemic blood stem cells"
	Claus Nerlov (MRC Molecular Hematology Unit, University of Oxford, UK) JSH-EHA Joint Symposium (Symposium 6):Evolving Paradigm for Blood Cell Differentiation "The hierarchical organisation of haematopoiesis"
	David Lillicrap (Pathology & Molecular Medicine, Richardson Laboratory, Queen's University, Kingston, Canada) Symposium 7:Advances and Innovations in Hemophilia Research "How do factor VIII and von Willebrand factor exit the circulation?"
	Johannes Oldenburg (Institute of Experimental Haematology and Transfusion Medicine, University Clinic Bonn, Germany) Symposium 7:Advances and Innovations in Hemophilia Research "Recent Clinical Trials for Haemophilia Therapy"
	Timothy Graubert (Massachussets General Hospital, Boston, Massachusetts, USA) JSH-ASH Joint Symposium(Symposium 8):Recent Advances in Myelodysplastic Syndromes "Genome analysis of MDS"
	Guillermo Garcia-Manero (The University of Texas MD Anderson Cancer Center, USA) JSH-ASH Joint Symposium(Symposium 8):Recent Advances in Myelodysplastic Syndromes "Advanced therapy in MDS"
	Adolfo Ferrando (Institute for Cancer Genetics, Columbia University, USA) Symposium 9:the Onset and Relapse of Pediatric Leukemia: How Did It Get to Here? "Genetics and mechanisms of chemotherapy resistance in acute lymphoblastic leukemia"
	Mark John Smyth (QIMR Berghofer Medical Research Institute, Australia) Symposium 10:Advances in Pathogenesis and Therapeutic Strategies of Multiple Myeloma in the Novel Agents Era "Mechanisms of immunity in blood cancers"
	Suzanne Trudel (Medical Oncology/Hematology, Princess Margaret Cancer Centre, Canada) Symposium 10:Advances in Pathogenesis and Therapeutic Strategies of Multiple Myeloma in the Novel Agents Era "Antibody drug conjugates for the treatment of multiple myeloma(MM)"
	Jae Park (Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, USA) Educational Lecture 1-11C "Treatment of relapsed/refractory All"
	Laurie H. Sehn (BC Cancer Centre for Lymphoid Cancer/Division of Medical Oncology, University of British Columbia, Canada) Educational Lecture 2-2F "Standard of care for DLBCL"
	Suning Chen (Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, China) Asian Joint Panel Discussion:Current Status of Acute Myeloid Leukemia / Myelodysplastic Syndromes in Asian Countries "Current status of acute myeloid leukemia in China"
	Hsin-An Hou (Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, College of Medicine, National Taiwan, University, Taiwan) Asian Joint Panel Discussion:Current Status of Acute Myeloid Leukemia / Myelodysplastic Syndromes in Asian Countries "Epidemiology and survival outcomes of acute myeloid leukemia: A national population-Based analysis in Taiwan"
	Pimjai Niparuck (Ramathibodi Hospital, Mahidol University, Thailand) Asian Joint Panel Discussion:Current Status of Acute Myeloid Leukemia / Myelodysplastic Syndromes in Asian Countries "The time keeps changing: Do the AML/MDS practices in Thailand change"
	Hee-Je Kim (Department of Hematology, Catholic Hematology Hospital, Leukemia Research Institute, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea) Asian Joint Panel Discussion:Current Status of Acute Myeloid Leukemia / Myelodysplastic Syndromes in Asian Countries "Current situation of KSH AML/MDS WP and recent therapeutic approaches against AML in Korea"
	Soniya Nityanand (Dept. of Hematology & Stem Cell Research Center, Sanjay Gandhi Post Graduate Institute of Medical Sciences, India) Asian Joint Panel Discussion:Current Status of Acute Myeloid Leukemia / Myelodysplastic Syndromes in Asian Countries "Current status of acute myeloid leukemia in India"
	Melissa G. Ooi (Department of Haematology Oncology, National University Hospital Singapore, Singapore / Department of Medicine, Yong Loo Lin School of Medicine, National University Singapore, Singapore) Asian Joint Panel Discussion:Current Status of Acute Myeloid Leukemia / Myelodysplastic Syndromes in Asian Countries "Treatment landscape of acute myeloid leukaemia in Singapore"